Related Content
Feature | Stents Bioresorbable| Dave Fornell, Editor
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology has ...
October 12, 2018
October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom ...
October 12, 2018
November 7, 2016 — The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3 ...
November 07, 2016
June 5, 2015 - REVA Medical Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its ...
June 05, 2015
February 12, 2015 — A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The ...
February 12, 2015
December 31, 2014 — Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. The ...
December 31, 2014
Feature | Stents Bioresorbable| Dave Fornell
(UPDATE: read the Sept. 8, 2017 article "Abbott Will End Sales of Absorb Bioresorbable Stent") A key prediction for ...
September 03, 2014
January 23, 2014 — An implant of the ReZolve2 bioresorbable scaffold was transmitted live via satellite at the ...
January 23, 2014April 2, 2013 — Reva Medical Inc. announced that it has initiated patient enrollment into a clinical trial with its ...
April 02, 2013
July 16, 2012 — Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting bioresorbable ...
July 16, 2012